Navigation Links
Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research

Survival update and prognostic factor analysis of oxaliplatin (ox) and irinotecan (iri) combinations in patients with metastatic colorectal cancer (MCRC).

    -- An updated analysis of the phase III N9741 study evaluating FOLFOX4

       versus irinotecan-based chemotherapy in metastatic colorectal cancer

       patients will be presented.

    -- Monday, June 4, 8:00 AM - 12:00 PM, S Hall A2, Poster Presentation.

Abstract # LBA5 - Final results of the EORTC Intergroup randomized phase III study 40983: Peri-operative FOLFOX4 chemotherapy and surgery for resectable liver metastases from colorectal cancer.

    -- The study examines the use of chemotherapy with oxaliplatin/5FU/LV

       (FOLFOX4) given before and after surgery of liver metastases from

       metastatic colorectal cancer versus surgery alone.  Eloxatin(R) for

       peri-operative use is not in the U.S. label.

    -- Monday, June 4, 3:30 PM - 3:45 PM, N Hall B1, Plenary Session.

For information about currently approved uses of Eloxatin(R), please see full prescribing information.

Taxotere(R) (docetaxel) Injection Concentrate clinical studies:

Abstract # LBA1008 - BCIRG007: First overall survival analysis of a randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC).

    -- This study evaluates the use of two Taxotere(R) - Herceptin

       (trastuzumab) regimens for the treatment of metastatic HER2 positive

       breast cancer patients.

    -- Sunday, June 3, 9:45 AM - 10:00 AM, N Hall B1, Oral Presentation.

Abstract #537 - Estrogen receptor expression and efficacy of docetaxel in early breast cancer: A pooled analysis of 3490 patients included in two randomized trials.

    -- This presentation reviews the use of Taxotere(R) in trials involving

       patients with early stage node positive breast cancer, accor
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:1/23/2015)... Partnership to Fight Chronic Disease (PFCD) released a public opinion poll ... new study analyzing the impact of increased cost sharing on patient ... to educate policy makers and the public on the costs of ... how the Iowa healthcare exchange could be ...
(Date:1/23/2015)... 2015  MedScope ( www.medscope.org ), the leading provider of ... Connected World magazine Connected World Award for ... can be used anywhere, anytime. The nomination was made ... In nominating MedScope, Landon Garner , Director of ...
(Date:1/23/2015)... 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is investigating ... Inc. ("Advaxis" or the "Company") (NASDAQ: ADXS ... duties to shareholders. On January 21, 2015, ... that Advaxis had misrepresented the clinical data for its ...
Breaking Medicine Technology:New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District ... against C.R. Bard, Inc. in that proceeding’s first bellwether trial. ... defense request for a new trial after finding that C.R. ...
(Date:1/22/2015)... has released a new blog post explaining the main features ... , Auto insurance quotes help many drivers find the best ... call an agent or visit an agency for price information. ... http://autocarinsurancebest.com/ . , Every business who relies heavily on ...
(Date:1/22/2015)... 2015 A study recently published ... journal Medicine & Science in Sports & Exercise ... help reduce gastrointestinal (GI) problems associated with physical ... in the double-blind, placebo-controlled study took 10 grams ...
(Date:1/22/2015)... 22, 2015 Four years since the release of ... coincided with the marriage of Avasa & Matthew Love – the ... is scheduled for release through White Swan Records on February 24, ... is a sacred path available to all of us to walk ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store for wedding dresses ... latest collection of wedding dresses , and launches a site-wide ... wedding dress on your big day; the wedding gown is ... wants to find the most suitable wedding dress. Now, we ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... 26, 2010 Global scientific, technical, medical and scholarly ... clinical decision support product, Essential Evidence Plus (EE+), is ... move can now easily find answers to challenging point-of-care ... other Smartphones. EE+ is accessible through ...
... The National Institute of Diabetes and Digestive and Kidney ... has awarded Albert Einstein College of Medicine of Yeshiva ... of its Diabetes Research and Training Center (DRTC). The ... equipment and additional pilot and feasibility studies through the ...
... from biologic meds, study finds , TUESDAY, May 25 ... less likely to be used by American rheumatoid arthritis ... with medical co-payments, a new study reveals. , Biologics, ... treat rheumatoid arthritis when more conventional treatments don,t work. ...
... spent less time in the hospital when treated using ... medical care focusing on increasing muscle motion in ... Kari Hortos, a Michigan State University professor in the ... one of seven site investigators as part of the ...
... ... Shore. , ... May 25, 2010 -- Blue Cross Blue Shield of Massachusetts, Inc. (BCBSMA) and ... Alternative Quality Contract (AQC). The agreement marks the first North Shore physician group ...
... ... Costs. Two of Southern California,s leading physician-governed medical groups, along with Anthem Blue Cross, ... rewards providers for improving patient outcomes, while slowing cost growth. , , ... (PRWEB) May 25, 2010 ...
Cached Medicine News:Health News:Mobile access now available for Essential Evidence Plus 2Health News:NIH awards $10M to Einstein for diabetes research 2Health News:NIH awards $10M to Einstein for diabetes research 3Health News:Out-of-Pocket Costs Limit Access to Arthritis Drugs 2Health News:Hands-on osteopathic treatment cuts hospital stays for pneumonia patients 2Health News:Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract 2Health News:Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract 3Health News:Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract 4Health News:Healthcare Partners, Monarch, and Anthem Blue Cross Chosen for Innovative National Healthcare Program 2Health News:Healthcare Partners, Monarch, and Anthem Blue Cross Chosen for Innovative National Healthcare Program 3Health News:Healthcare Partners, Monarch, and Anthem Blue Cross Chosen for Innovative National Healthcare Program 4
For the quantitative in vitro determination of Urea in serum, plasma and urine....
For the quantitative in vitro determination of K-glutamyl transferase (K-GT) in serum or plasma....
The CKMB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase MB isoenzyme activity in serum and plasma...
The XCHO method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of cholesterol in serum and plasma....
Medicine Products: